Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlates in gambling disorder
Baenas Soto, Isabel Maria (Hospital Universitari de Bellvitge)
Solé-Morata, Neus (Hospital Universitari de Bellvitge)
Granero, Roser (Universitat Autònoma de Barcelona. Departament de Psicobiologia i de Metodologia de Ciències de la Salut)
Fernández-Aranda, Fernando (Institut d'Investigació Biomèdica de Bellvitge)
Pujadas, Mitona (Institut Hospital del Mar d'Investigacions Mèdiques)
Mora-Maltas, Bernat (Hospital Universitari de Bellvitge)
Lucas, Ignacio (Hospital Universitari de Bellvitge)
Gomez-Peña, Mónica (Hospital Universitari de Bellvitge)
Moragas, Laura (Hospital Universitari de Bellvitge)
Del Pino-Gutiérrez, Amparo (Hospital Universitari de Bellvitge)
Tapia, Javier (Hospital Universitari de Bellvitge)
De La Torre, Rafael (Institut Hospital del Mar d'Investigacions Mèdiques)
Potenza, Marc N. (Yale University School of Medicine)
Jiménez-Murcia, Susana (Hospital Universitari de Bellvitge)

Data:	2023
Resum:	Introduction. Different components of the endocannabinoid (eCB) system such as their most well-known endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been implicated in brain reward pathways. While shared neurobiological substrates have been described among addiction-related disorders, information regarding the role of this system in behavioral addictions such as gambling disorder (GD) is scarce. Aims Fasting plasma concentrations of AEA and 2-AG were analyzed in individuals with GD at baseline, compared with healthy control subjects (HC). Through structural equation modeling, we evaluated associations between endocannabinoids and GD severity, exploring the potentially mediating role of clinical and neuropsychological variables. Methods. The sample included 166 adult outpatients with GD (95. 8% male, mean age 39 years old) and 41 HC. Peripheral blood samples were collected after overnight fasting to assess AEA and 2-AG concentrations (ng/ml). Clinical (i. e. , general psychopathology, emotion regulation, impulsivity, personality) and neuropsychological variables were evaluated through a semi-structured clinical interview and psychometric assessments. Results. Plasma AEA concentrations were higher in patients with GD compared with HC (p = . 002), without differences in 2-AG. AEA and 2-AG concentrations were related to GD severity, with novelty-seeking mediating relationships. Conclusions. This study points to differences in fasting plasma concentrations of endocannabinoids between individuals with GD and HC. In the clinical group, the pathway defined by the association between the concentrations of endocannabinoids and novelty-seeking predicted GD severity. Although exploratory, these results could contribute to the identification of potential endophenotypic features that help optimize personalized approaches to prevent and treat GD.
Ajuts:	Instituto de Salud Carlos III PI20/00132 Instituto de Salud Carlos III 847879
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	2-arachidonoylglycerol ; Addictive behaviors ; Anandamide ; Gambling disorder ; Impulsive behaviors
Publicat a:	European psychiatry, Vol. 66 Núm. 1 (2023) , ISSN 1778-3585

DOI: 10.1192/j.eurpsy.2023.2460
PMID: 37937379

9 p, 411.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats